Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
While some say this strategy's failure rate is "too high," it's one step closer to the "white grail" of a shorter 24-week formula.
Read Full NewsNot all adrenal incidentalomas need the same workup. The Curbsiders break down when to worry, what to test, and why MACS may be behind your patient's hard-to-control metabolic disease.
Dr Maurie Markman examines new registry data on ovarian cancer diagnostic timing, showing how disease biology can complicate the link between early detection and survival.
Dr Andrea Chadwick describes how the shift from tender points to symptom-based criteria has improved fibromyalgia diagnosis, understanding, and patient-centered care.
Dr Anne Peters discusses the expanding use of continuous glucose monitoring in people with diabetes.
Before you freeze a skin lesion, ask yourself whether you really know what it is. Here are four signs you should biopsy instead of freeze.
EyePoint said its experimental drug missed the main goal in a late-stage trial as a few patients lost vision from causes unrelated to the targeted disease, sending its...
The FDA has approved a radioactive agent for use in brain scans to help assess patients for Alzheimer's disease.
1.
Oncology Drug Shortages Persist, but Continue to Evolve
2.
New guidelines expand access to lung cancer screening, but gaps remain in reaching rural and uninsured populations
3.
Key mechanism behind prostate cancer drug resistance reveals potential new treatment strategy
4.
Novel analysis identifies markers that may predict failure of metastatic prostate cancer treatment
5.
Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy
1.
Practical Concepts in Hematology and Patient Outcomes
2.
Contemporary Insights in Oncology in the Digital Era
3.
Artificial Intelligence for Bone Marrow Cellular Ecosystem Modeling
4.
Real-World Evidence and Patient Voices: Redefining Outcomes in Modern Oncology
5.
Understanding the Importance of Knowing Your MCV Normal Range
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
2.
Navigating the Complexities of Ph Negative ALL - Part XVI
3.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
4.
Evidence-Based Oncology
5.
Efficient Management of First line ALK-rearranged NSCLC - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge